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Interest in the chemistry of pyridocarbazoles and indolo-
quinolines has increased this last decade since these skele-
tons are present in a large number of alkaloids of biological
interest. For example, the indoloquinoline type alkaloid cryp-
tolepine 1 (Fig. 1) extracted from the roots of Cryptolepis
sanguinolenta1) has been shown to exhibit antiplasmodial,2)
antibacterial3) and cytotoxic properties.4,5) This last activity is
due to cryptolepine intercalation into DNA and subsequent
inhibition of DNA religation by topoisomerase II.5) Another
example concerns the pyridocarbazole type alkaloid ellip-
ticine 2 (Fig. 1) extracted from the leaves of Ochrosia ellip-
tica6) which has exhibited cytotoxic properties by different
mechanisms : intercalation into DNA,7) inhibition of topoiso-
merase II,8) formation of covalent adducts with DNA after
bioactivation,9) stimulation of apoptosis.10) Different linear
and angular analogs of these compounds have already been
synthetized by several groups11—17) but the series of in-
dolo[2,3-c]quinoline and pyrido[2,3-c]carbazole haven’t been
studied yet.
Therefore, as a part of our program concerning the elabo-
ration of analogs of natural products, we are interested in the
chemistry as well as in the biological activities of these angu-
lar heterocycles.18,19) Our methodology resides in the photo-
cyclization of enaminones derived from 3 or 6-aminoquino-
line (Fig. 1). Enaminones represent convenient tools in hete-
rocyclic chemistry since they can be implicated in the elabo-
ration of carbazoles,20) a-carbolines,21) b-carbolines and d-
carbolines.22,23) The photocyclization can occur through an
electrocyclization for tertiary enaminones or through a radi-
cal process for halogenated enaminones.24) Furthermore, in
our recent works, we obtained N-benzylpyridocarbazoles and
indoloquinolines from tertiary N-benzylenaminones25) and
non N-substituted compounds from secondary iodinated
enaminones.26) In the present work, we investigate the reac-
tivity of tertiary enaminones carrying an alkyl or a dialky-
laminoalkyl side chain 3 and report the results of in vitro cy-
totoxicity studies of the obtained cyclized compounds 4.
Chemistry
Firtsly, the reactivity of tertiary enaminones derived from
3-aminoquinoline was studied. According to previously de-
scribed procedures,22,23,25,26) the secondary enaminone 7 is
obtained by condensation of 3-aminoquinoline 5 and 1,3-cy-
clohexandione 6 in toluene with catalytic amounts of p-tolue-
nesulfonic acid. Then, a methyl or a diethylaminoethyl side
chain was introduced on the enaminone nitrogen by treating
secondary enaminone 7 by sodium hydride, and then 
by methyl iodide or by the hydrochloride salt of diethyl-
aminoethylchloride to give 8 and 9. The dimethylamino-
propyl side chain couldn’t be introduced following this proto-
cole. However, the tertiary enaminone 10 was obtained by
treating compound 7 with the hydrochloride salt of dimethyl-
aminopropylchloride in presence of sodium hydride in di-
methylformamide (DMF)27) (Fig. 2).
The methyl substituent was chosen because structure–
activity relationships studies realized on ellipticine and cryp-
tolepine linear or angular analogs show the contribution of
the N-methyl function to the cytotoxicity and a frequent loss
of activity with bigger alkyl chains.11,28,29) Dialkylaminoalkyl
chains were chosen because they’re often described as cyto-
toxicity enhancers, probably through a stabilisation of the
drug–DNA interaction.30,31)
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Indoloquinoline alkaloid cryptolepine and pyridocarbazole alkaloid ellipticine are of great interest because
in vitro and in vivo studies revealed their good cytotoxic properties. In order to obtain some biologically active
analogs of these compounds, we developed a synthesis based on the photocyclization of tertiary N-substituted
enaminones derived from 1,3-cyclohexandione and 3 or 6-aminoquinoline. The angular cyclized compounds thus
obtained were tested in vitro on K 562 cells and A 2780 doxorubicin sensitive and resistant cells. All compounds
were less effective than doxorubicin in sensitive cells but their activity wasn’t decreased by MDR resistance.
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Fig. 1
Irradiation of enaminones 8, 9, 10 to give respectively 11,
12, 13, were performed using a Pyrex well apparatus and a
medium pressure mercury UV lamp (150 W) under a set of
conditions (Fig. 3, Table 1).
These photocyclizations were regioselective on the C-4
position of the quinolinic nucleus since only angular com-
pounds were obtained. Structure of 11, 12, 13 was easily de-
termined by 1H-NMR, and by comparison with our previous
results.25,26) More precisely the 1H-NMR spectrum of 11, 12,
13 showed characteristic signals of H-1 shifted downfield due
to the proximity of the carbonyl group and appeared as dou-
ble doublets (d 9.68 for 11, d 9.81 for 12, d 9.74 for 13). The
N-substituents don’t change the regioselectivity previously
observed with N-benzylated enaminones25) and with second-
ary iodinated enaminones.26) Yields of photocyclization were
close to those previously obtained: Compound 11 was ob-
tained with the best yield (80%) with methanol as solvent,
while the substituted indoloquinolines 12 and 13 were ob-
tained respectively with a 60% and a 35% yield (other condi-
tions led to massive decomposition of the enaminone and
poor yields of cyclized compounds). Compounds 11, 12 and
13 were retained for biological studies.
Then, so as to study the influence of the position of the
quinolinic nitrogen on the reactivity of such enaminones, the
secondary enaminone 15 was prepared by condensation of 
6-aminoquinoline 14 and 1,3-cyclohexandione 6 in toluene
with p-toluenesulfonic acid. Then, tertiary enaminones 16,
17 and 18 were obtained by treatment of 15 with sodium hy-
dride in toluene and then, by methyl iodide, ethyl iodide or
diethylaminoethyl hydrochloride. Tertiary enaminone 19 was
also obtained by treatment of 15 with dimethylaminopropyl-
chloride hydrochloride in DMF in presence of sodium hy-
dride (Fig. 4). The N-ethyl derivative 17 was prepared be-
cause the first biological results showed a better activity of
the 6-aminoquinoline derivatives, so we wanted to test other
alkyl side chains, with the hope of increasing cytotoxicity.
Then, these four tertiary enaminones were subjected to ir-
radiation in a pyrex reactor under different conditions (Fig. 5,
Table 2).
The results of these irradiations were quite surprising,
since we obtained a mixture of the expected 8,9,10,11-
tetrahydropyridocarbazoles 24, 25, 26, and 27 and of
5,6,8,9,10,11-hexahydropyridocarbazoles 20, 21, 22 and 23.
In all cases, only angular compounds, identified easily thanks
to the chemical shift of proton H-1, were obtained, confirm-
ing the perfect regioselectivity of this photocyclization. The
global yields of photocyclization were smaller than those ob-
tained with 3-aminoquinoline derivatives and confirm the
lower reactivity of 6-aminoquinoline derivatives, previously
described.25,26) As the influence of solvent is a well-known
phenomenon in photochemistry, it was hypothetised that irra-
diation in another solvent such as toluene could modify the
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Table 1. Irradiation of Tertiary Enaminones 8, 9, 19
Entry Substrate Conditions
Yield (%)
of compd.
1 8 RCH3 Pyrex, methanol, 4 h 11 (80)
2 8 RCH3 Pyrex, toluene, 4 h 11 (55)
3 8 RCH3 Pyrex, methanol/toluene 50/50, 4 h 11 (70)
4 9 R(CH2)2N(Et)2 Pyrex, methanol, 4 h 12 (60)
5 10 R(CH2)3N(Me)2 Pyrex, methanol, 4 h 13 (35)
Table 2. Irradiation of Tertiary Enaminones 16, 17, 18, 19
Entry Substrate Conditions Yield (%) of compd. Global yield (%)
1 16 RCH3 Pyrex, methanol, 4 h 20 (56) and 24 (44) 40
2 17 RCH2CH3 Pyrex, methanol, 4 h 21 (85) and 25 (15) 50
3 18 R(CH2)2N(Et)2 Pyrex, methanol, 4 h 22 (95) and 26 (5) 40
4 19 R(CH2)3N(Et)2 Pyrex, methanol, 4 h 23 (80) and 27 (20) 40
5 16 RCH3 Pyrex, toluene, 4 h 20 (40) and 24 (60) 50
6 17 RCH2CH3 Pyrex, toluene, 4 h 21 (5) and 25 (95) 40
7 18 R(CH2)2N(Et)2 Pyrex, toluene, 4 h 22 (10) and 26 (90) 25
8 19 R(CH2)3N(Et)2 Pyrex, toluene, 4 h 23 (25) and 27 (75) 60
ratio hexahydro/terahydro compound. So, compounds 16, 17,
18 and 19 were irradiated in a pyrex reactor in toluene for
4 h. The ratios reduced/non reduced compound were reversed
and non-reduced compounds were largely predominant, ex-
cept in the case of the N-methyl derivative, whose photocy-
clization seemed to be poorly influenced by the solvent of ir-
radiation.
This C5–C6 bond reduction had already been established
when photocyclization of secondary iodinated enaminone de-
rived from 6-aminoquinoline was conducted in a pyrex reac-
tor using acetonitrile with 4 ml of triethylamine as solvent.26)
Only the hexahydro compound was obtained. Furthermore,
this reduction could be understood as the result of a photoin-
duced electron transfer from triethylamine to the aromatic
system, followed by abstraction of a proton and an hydrogen
radical from the solvent, as described by Yang et al.32) But, in
the present case, the reaction mixture didn’t contain any tri-
ethylamine, so this phenomenon can’t explain the photore-
duction. 6p electron mechanism is implicated in the photo-
cyclization of such tertiary enaminones. According to this
mechanism, described by Grellman et al.33) and Chapman et
al.,34) a zwitterionic species is initially formed, which gives a
hexahydro compound, which can eventually undergo a dehy-
drogenation process to give a tetrahydro compound. Further-
more, Grellman et al.35) have irradiated the N-methyl-2-anili-
nonaphtalene 28 in different solvents and have obtained a
mixture of 5-methylbenzo[c]carbazole 29 and 5-methyl-6,7-
dihydrobenzo[c]carbazole 30 (2 : 1 ratio). A hypothesis was
proposed by the authors to explain the formation of those two
compounds: after the electrocyclisation, the zwitterionic in-
termediate 31 undergoes a suprafacial 1,4 hydrogen shift.
The resulting compound 32 can either undergo an internal re-
arrangement to give 30 or undergo dehydrogenation to give
29 (Fig. 6).
This hypothesis can be applied to our compounds and
therefore may explain the results presented above: irradiation
of tertiary enaminones 16, 17, 18, 19 should give the inter-
mediary hexahydro derivatives 33, 34, 35, 36. Toluene in-
duces dehydrogenation to give 24, 25, 26, 27 whereas
methanol induces rearrangement to give 20, 21, 22, 23, as
shown in Fig. 7.
A second phenomenon which happens after cyclization
and dehydrogenation might explain C5–C6 bond reduction.
Some authors36—38) described the reduction of one bond 
of aromatic compounds when they underwent irradiation 
in proton donnors solvents, particularly aliphatic alcohols.
Methanol could contribute to the reduction via this pathway.
However, this phenomenon doesn’t explain the formation of
reduced compounds when the N-substituted derivatives were
irradiated in toluene alone. Yet we can reasonably suppose
that solvent influence on the rearrangement or the dehydro-
genation is the most important phenomenon and that pho-
toreduction of tetrahydro cyclized compound by methanol
may contribute to the formation of reduced compounds.
Finally, we investigated the strategy which consist in treat-
ing reduced compounds by Pd/C 10% in diphenylether.39)
This reaction was successful in the case of the non-N-substi-
tuted pyridocarbazole 3726) which gave the compound 3826)
with a 30% yield. N-Methyl and N-ethyl compounds 24 and
25 were obtained from 20 and 21 with a 30% yield. But, un-
fortunately, compounds 22 and 23 underwent massive degra-
dation (Fig. 8).
Biological Results
In continuation of our previous works40,41) concerning the
antiproliferative activity of tetracyclic nitrogenous heterocy-
cles, and more precisely, their activity against MDR cancer
cells lines, the cytotoxicity of the compounds 11, 12, 13, 
24, 25, 26, 37, 38 and 39, as the non N-substituted indolo-
quinoline previously prepared26) was evaluated by a cell
growth inhibition assay against two human cell lines: K 562
(leukemia), and A 2780 (ovarian cancer) doxorubicin-sensi-
tive and resistant (MDR) and was compared to the cytotox-
icity of doxorubicin. The resistant subline A 2780 R was es-
tablished by the continuous exposure of cells to gradually in-
creasing concentrations of doxorubicin. The resistant subline
K 562 R wasn’t tested because of the poor activity of our
products against K 562 S cells. IC50 (concentration inhibiting
50% of the cell proliferation) expressed in mol/l and resist-
ance factor (IC50 on A2780 resistant cells/IC50 on A2780
sensitive cells) of each compound are recapitulated in Table
3.
All the compounds are 10 to 1000 fold less effective than
doxorubicin in all sensitive cells whereas compounds 11, 24
and 26 are as active as doxorubicin on A 2780 resistant cells
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with IC50 varying between 2.8 and 8.310
6 mol/l. The other
compounds are only 10 fold less active than doxorubicin on
A 2780 R cells. The resistance factor of all those compounds
varies between 1 and 2.9 (doxorubicin: 121), which indicates
that these compounds, as most synthetic compounds, are not
concerned by the multidrug resistance phenomenon.
Comparison of IC50 values of the hexahydro compound 37
and the tetrahydro compound 38 shows this reduction doesn’t
seem to influence the biological activity, in spite of the
twisted structure of the reduced compound. Whatever the N-
substituent is, IC50 of 3-aminoquinoline derivatives are, in
most cases, equal or higher than IC50 of 6-aminoquinoline
derivatives, proving that 6-aminoquinoline series gives more
active compounds. About the influence of the N-substituent,
it appears that the N-methyl compound 11 is the most active
of the 3-aminoquinoline derivatives and that N-methyl and N-
diethylaminoethyl compounds 24 and 26 are the most active
of the 6-aminoquinoline derivatives, thus proving the role of
the N-methyl group in the cytotoxic activity and the role of
dialkylaminoalkyl side chains in cytotoxicity enhancement.
Compounds 11, 24 and 26, the most active ones, are good
candidates for further in vivo studies.
Conclusion
In this paper, we have reported the synthesis of N-substi-
tuted tetracyclic nitrogen heterocycles: indoloquinolines 
and pyridocarbazoles. The photochemical key step which
provides cyclized compounds from N-alkyl or N-dialkyl-
aminoalkyl enaminones occures with a total regioselectivity,
since only angular compounds are obtained. An unexpected
photoreduction phenomenon occured during irradiation and
was shown to be greatly influenced by the solvent. The first
in vitro studies reveal that the main interest of these com-
pounds resides in their activity toward resistant cells. Further
studies on the pharmacomodulation of such compounds are
now in progress and should lead to an interesting class of
new potential anticancer agents with no multidrug resistance
phenomena.
Experimental
1H- and 13C-NMR spectra were recorded on a Brüker AC 100 or EM 400
WB. Chemical shift data are reported in ppm downfield d from TMS. Cou-
pling constants J are given in Hz. s, d, dd, t, q, and m mean respectively sin-
glet, doublet, double doublet, triplet, quadruplet and multiplet. Melting
points were determined on a Büchi capillary melting point apparatus and are
not corrected. Elemental analysis was performed by Microanalytical center,
ENSCM, Montpellier.
Irradiations were conducted in a pyrex well apparatus using a medium
pressure mercury UV lamp (Heraeus TQ 150). Total volume of solvent(s)
was about 350—400 ml. In order to remove oxygen, the reaction mixture
was submitted to ultrasound waves for 10 min before irradiation. Besides,
during the irradiation, the reaction mixture was flushed with a stream of 
nitrogen.
3-[(3-Quinolinyl)methylamino]cyclohex-2-en-1-one 8 Compound 7
(1 g, 4.2 mmol) was added to a suspension of sodium hydride (1 g, 25 mmol,
60% in mineral oil) in anhydrous toluene (50 ml). The mixture was refluxed
under nitrogen for 2 h and cooled to room temperature. Methyl iodide (5 ml,
80 mmol) was then added and the mixture was refluxed for 3 h. After cool-
ing, toluene was washed with water and the insoluble residue was dissolved
in dichloromethane and washed with water. The organic layers were dried
over sodium sulfate and evaporated in vacuo. The crude product was chro-
matographed on silica gel with dichloromethane and a gradient of methanol
as eluent to give 8 as a white powder: 45%, mp 128—130 °C. 1H-NMR
(CDCl3) d : 1.91 (2H, m), 2.28 (4H, m), 3.32 (3H, s), 5.37 (1H, s), 7.58 (1H,
m), 7.76 (2H, m), 7.90 (1H, d, J2.2 Hz), 8.11 (1H, d, J8.1 Hz), 8.71 (1H,
d, J2.3 Hz); 13C-NMR (CDCl3) d : 22.2, 29.3, 35.8, 40.7, 101.7, 127.4
(3C), 129.0, 129.7, 132.5, 138.4, 146.3, 149.4, 164.2, 197.3; Anal. Calcd for
C16H16N2O: C, 76.19; H, 6.35; N, 11.11. Found: C, 76.30; H, 6.35; N, 11.08.
3-[(3-Quinolinyl)diethylaminoethylamino]cyclohex-2-en-1-one 9
Compound 7 (0.5 g, 2.1 mmol) was added to a suspension of sodium hydride
(1 g, 25 mmol, 60% in mineral oil) in anhydrous toluene (50 ml). The mix-
ture was refluxed under nitrogen for 2 h and cooled to room temperature. Di-
ethylaminoethylchloride hydrochloride (0.4 g, 2.3 mmol) was then added and
the mixture was refluxed for 2 h. After cooling, toluene was washed with
water and the insoluble residue was dissolved in dichloromethane and
washed with water. The organic layers were dried over sodium sulfate and
evaporated in vacuo. The crude product was chromatographed on alumina
gel with ether and a gradient of methanol as eluent to give 9 as a yellow oil:
35%. 1H-NMR (CDCl3) d : 0.88 (6H, t, J7.0 Hz), 1.89 (2H, m), 2.26 (4H,
m), 2.42 (q, 4H, J7.0 Hz), 2.67 (2H, t, J6.9 Hz), 3.73 (2H, t, J6.9 Hz),
5.35 (1H, s), 7.69 (3H, m), 8.1 (2H, m), 8.75 (1H, d, J2.3 Hz); 13C-NMR
(CDCl3) d : 11.3 (2C), 22.0, 29.1, 35.6, 46.7 (2C), 49.6, 51.3, 101.1, 127.0,
127.2, 128.8, 129.4, 133.3, 137.5, 146.1, 150.2, 163.5, 196.8. Anal. Calcd
for C21H27N3O: C, 74.78; H, 8.01; N, 12.46. Found: C, 74.61; H, 8.02; N,
12.37.
3-[(3-Quinolinyl)dimethylaminopropylamino]cyclohex-2-en-1-one 10
Compound 7 (0.5 g, 2.1 mmol) and dimethylaminopropylchloride hydrochlo-
ride (0.4 g, 2.53 mmol) were added to a suspension of sodium hydride (1 g,
25 mmol, 60% in mineral oil) in dimethylformamide (10 ml). The mixture
was refluxed under nitrogen for 3 h and cooled to room temperature. Then,
methanol was added to neutralize sodium hydride excess, followed by water
(30 ml). After extraction with dichloromethane (350 ml), the organic layers
were dried over sodium sulfate and evaporated in vacuo. The crude product
was chromatographed on silica gel with ether and a gradient of methanol as
eluent to give 10 as a yellow oil: 34%. 1H-NMR (CDCl3) d : 1.87 (4H, m),
2.11 (6H, s), 2.26 (6H, m), 3.70 (2H, t, J7.3 Hz), 5.35 (1H, s), 7.71 (4H,
m), 8.11 (1H, d, J8.3 Hz), 8.67 (1H, d, J2.2 Hz); 13C-NMR (CDCl3) d :
22.7, 25.4, 29.0, 36.4, 45.6, 51.6, 56.7, 101.9, 128.0, 128.0, 128.2 (3C),
129.6, 130.4, 134.2, 137.6, 147.0, 150.6, 164.5, 197.8. Anal. Calcd for
C20H25N3O: C, 74.30; H, 7.74; N, 13.0. Found: C, 74.50; H, 7.76; N, 12.89.
7-Methyl-8,9,10,11-tetrahydroindolo[2,3-c]quinolin-11-one 11 Com-
pound 8 (0.4 g, 1.6 mmol) underwent irradiation under different conditions
(see Table 1). Then, the solvents were evaporated under reduced pressure. The
crude product was chromatographed on silica gel using dichloromethane and
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Table 3. IC50 and Resistance Factor of Tested Compounds and Doxorubicin
Compds.
K 562 cells A 2780 sensitive cells A 2780 resistant cells
RFa)
(mol/l) (mol/l) (mol/l)
11 4.61052.8106 8.01066.3106 8.31064.0107 1
12 2.11051.0106 4.01052.6105 9.01052.8106 2.3
13 1.51051.0106 3.81053.2106 9.51051.1106 2.5
24 3.31052.0106 2.01061.0106 5.81062.4106 2.9
25 7.81061.8106 1.41055.9106 1.71051.0105 1.2
26 2.51053.0106 2.81061.7106 2.81061.8107 1
37 8.81051.3105 2.21051.1105 2.81052.0105 1.3
38 2.31051.2106 1.41057.8105 2.51054.6106 1.8
39 9.31052.6105 3.31054.2105 4.21055.5106 1.3
Doxb) 1.61073.3108 2.41084.0109 2.91064.9107 121
a) resistance factor, b) doxdoxorubicin.
a gradient of methanol as eluent to give 11 as a white powder: 80% (best
yield), mp 238—240 °C. 1H-NMR (CDCl3) d : 2.08 (2H, m), 2.35 (2H, t,
J6.2 Hz), 2.54 (2H, t, J6.3 Hz), 3.16 (3H, s), 7.63 (2H, m), 8.12 (1H, dd,
J6.7, 1.5 Hz), 8.52 (1H, s), 9.68 (1H, dd, J6.6, 1.5 Hz); 13C-NMR
(CDCl3) d : 22.2, 22.5, 29.9, 39.0, 114.7, 123.3, 125.9, 126.2, 127.4, 128.6,
129.5, 129.9, 135.3, 144.3, 152.7, 193.4. Anal. Calcd for C16H14N2O: C,
76.80; H, 5.60; N, 11.20. Found: C, 76.75; H, 5.62; N, 11.17.
7-(N,N-Diethylaminoethyl)-8,9,10,11-tetrahydroindolo[2,3-c]quinolin-
11-one 12 Compound 9 (0.3 g, 0.9 mmol) underwent irradiation for 2 h in
a pyrex reactor using methanol as solvent. Then, the solvents were evapo-
rated under reduced pressure. The crude product was chromatographed on
silica gel using dichloromethane and a gradient of methanol as eluent to give
12 as a yellow oil: 60% (best yield). 1H-NMR (CDCl3) d : 0.86 (6H, t,
J6.7 Hz), 2.24 (2H, m), 2.47 (4H, q, J6.7 Hz), 2.74 (4H, m), 2.99 (2H, t,
J6.1 Hz), 4.19 (2H, t, J6.8 Hz), 7.64 (2H, m), 8.15 (1H, m), 8.95 (1H, s),
9.81 (1H, m); 13C-NMR (CDCl3) d : 11.60 (2C, CH3 4), 22.39 (2C, C8, C9),
38.80 (C10), 43.09 (CH2 1), 47.55 (2C, CH2 3), 52.55 (CH2 2), 114.49
(C11a), 123.19 (C11b), 125.71 (C3), 125.95 (C11c), 126.63 (C2), 128.22
(C1), 129.00 (C4), 129.27 (C6a), 135.38 (C6), 144.09 (C4a), 152.58 (C7a),
193.00 (C11). Anal. Calcd for C21H25N3O: C, 75.22; H, 7.46; N, 12.54.
Found: C, 75.34; H, 7.45; N, 12.48.
7-(N,N-Dimethylaminopropyl)-8,9,10,11-tetrahydroindolo[2,3-
c]quinolin-11-one 13 Compound 10 (0.23 g, 0.7 mmol) underwent irradia-
tion for 2 h in a pyrex reactor using methanol as solvent. Then, the solvents
were evaporated under reduced pressure. The crude product was chro-
matographed on alumina gel using dichloromethane and a gradient of
methanol as eluent to give 13 as an orange oil: 35% (best yield). 1H-NMR
(CDCl3) d : 1.81 (2H, m), 2.06 (2H, m), 2.09 (6H, s), 2.15 (2H, t, J6.4 Hz),
2.57 (2H, t, J6.1 Hz), 2.76 (2H, t, J6.2 Hz), 4.02 (2H, t, J7 Hz), 7.58
(2H, m), 8.08 (1H, m), 8.86 (1H, s), 9.74 (1H, m); 13C-NMR (CDCl3) d :
22.8, 23.1, 28.2, 39.4, 41.8, 45.6, 55.8, 115.3, 123.7, 126.4, 126.7, 127.5,
128.4, 129.5, 130.1, 136.0, 144.7, 152.7, 193.5. Anal. Calcd for C20H23N3O:
C, 74.77; H, 7.17; N, 13.08. Found: C, 74.80; H, 7.20; N, 12.99.
3-[(6-Quinolinyl)methylamino]cyclohex-2-en-1-one 16 Compound
15 (1 g, 4.2 mmol) was added to a suspension of sodium hydride (1 g,
25 mmol, 60% in mineral oil) in anhydrous toluene (50 ml). The mixture was
refluxed under nitrogen for 2 h and cooled to room temperature. Methyl 
iodide (5 ml, 80 mmol) was then added and the mixture was stirred for 24 h
at 80 °C. After cooling, toluene was washed with water and the insoluble
residue in the balloon flask was dissolved in dichloromethane and also
washed with water. The organic layers were dried over sodium sulfate and
evaporated in vacuo. The crude product was chromatographed on alumina
gel with ether and a gradient of methanol as eluent to give 16 as a yellow
powder: 40%, mp 134—136 °C. 1H-NMR (CDCl3) d : 1.87 (2H, m), 2.27
(4H, m), 3.30 (3H, s), 5.35 (1H, s), 7.49 (3H, m), 8.12 (2H, m), 8.92 (1H, d,
J3.6 Hz); 13C-NMR (CDCl3) d : 22.3, 28.4, 35.9, 40.6, 101.2, 121.7, 125.0,
128.3, 128.6, 131.1, 135.6, 143.0, 146.7, 150.8, 164.4, 197.3. Anal. Calcd
for C16H16N2O: C, 76.19; H, 6.35; N, 11.11. Found: C, 76.27; H, 6.37; N,
11.09.
3-[(6-Quinolinyl)ethylamino]cyclohex-2-en-1-one 17 Compound 15
(1 g, 4.2 mmol) was added to a suspension of sodium hydride (1 g, 25 mmol,
60% in mineral oil) in anhydrous toluene (50 ml). The mixture was refluxed
under nitrogen for 2 h and cooled to room temperature. Ethyl iodide (3 ml,
38 mmol) was then added and the mixture was stirred for 24 h at 80 °C.
After cooling, toluene was washed with water and the insoluble residue in
the balloon flask was dissolved in dichloromethane and also washed with
water. The organic layers were dried over sodium sulfate and evaporated in
vacuo. The crude product was chromatographed on alumina gel with
dichloromethane and a gradient of methanol as eluent to give 17 as a yellow
oil: 37%. 1H-NMR (CDCl3) d : 1.14 (3H, t, J7.1 Hz), 1.82 (2H, m), 2.17
(2H, t, J6.1 Hz), 2.23 (2H, t, J6.2 Hz), 3.66 (2H, q, J7.1 Hz), 5.29 (s,
1H), 7.38 (m, 2H), 7.52 (1H, d, J2.3 Hz), 8.1 (2H, m), 8.87 (1H, dd,
J4.2, 1.6 Hz); 13C-NMR (CDCl3) d : 12.5, 22.8, 29.0, 36.4, 48.0, 101.0,
122.3, 126.7, 128.8, 130.1, 130.7, 136.3, 141.8, 147.3, 151.4, 164.5, 198.0.
Anal. Calcd for C17H18N2O: C, 76.70; H, 6.77; N, 10.53. Found: C, 76.58; H,
6.77; N, 10.57.
3-[(6-Quinolinyl)diethylaminoethylamino]cyclohex-2-en-1-one 18
Compound 15 (0.75 g, 3.2 mmol) was added to a suspension of sodium hy-
dride (2 g, 50 mmol, 60% in mineral oil) in anhydrous toluene (50 ml). The
mixture was refluxed under nitrogen for 2 h and cooled to room temperature.
Diethylaminoethylchloride hydrochloride (0.5 g, 2.9 mmol) was then added
and the mixture was refluxed for 2 h. After cooling, toluene was washed with
water and the insoluble residue in the balloon flask was dissolved in
dichloromethane and also washed with water. The organic layers were dried
over sodium sulfate and evaporated in vacuo. The crude product was chro-
matographed on alumina gel with ether and a gradient of methanol as eluent
to give 18 as a yellow oil: 28%. 1H-NMR (CDCl3) d : 0.87 (6H, t, J7.1 Hz,
CH3 4), 1.84 (2H, m), 2.21 (2H, t, J6.2 Hz), 2.24 (2H, t, J6.3 Hz), 2.40
(4H, q, J7.1 Hz), 2.63 (2H, t, J7.3 Hz), 3.70 (2H, t, J7.1 Hz), 5.30 (1H,
s), 7.38 (1H, m), 7.49 (1H, dd, J8.9, 2.4 Hz), 7.62 (1H, d, J2.2 Hz), 8.07
(2H, m), 8.87 (1H, dd, J4.2, 1.6 Hz); 13C-NMR (CDCl3) d : 12.2 (2C),
22.9, 29.7, 36.4, 47.6 (2C), 50.3, 52.0, 101.4, 122.2, 126.6, 128.8, 130.2,
131.5, 136.2, 142.6, 147.3, 151.4, 164.7, 197.9. Anal. Calcd for C21H27N3O:
C, 74.78; H, 8.01; N, 12.46. Found: C, 74.84; H, 8.03; N, 12.49.
3-[(6-Quinolinyl)dimethylaminopropylamino]cyclohex-2-en-1-one 19
Compound 15 (0.5 g, 2.1 mmol) and dimethylaminopropylchloride hy-
drochloride (0.4 g, 2.53 mmol) were added to a suspension of sodium hy-
dride (1 g, 25 mmol, 60% in mineral oil) in dimethylformamide (10 ml). The
mixture was refluxed under nitrogen for 3 h and cooled to room temperature.
Then, methanol was added to neutralize sodium hydride excess, followed by
water (30 ml). After extraction with dichloromethane (350 ml), the organic
layers were dried over sodium sulfate and evaporated in vacuo. The crude
product was chromatographed on alumina gel with ether and a gradient of
methanol as eluent to give 19 as a yellow oil: 45%. 1H-NMR (CDCl3) d :
1.82 (2H, m, H5), 1.91 (2H, m), 2.13 (6H, s), 2.27 (6H, m), 3.72 (2H, t,
J7.7 Hz), 5.36 (1H, s), 7.46 (2H, m), 7.59 (1H, d, J2.3 Hz), 8.13 (2H, m),
8.94 (1H, dd, J4.2, 1.6 Hz); 13C-NMR (CDCl3) d : 22.8, 25.4, 29.0, 36.4,
45.7, 51.4, 56.8, 101.2, 122.2, 126.6, 128.8, 129.9, 131.7, 136.2, 142.0,
147.2, 151.4, 164.8, 197.8. Anal. Calcd for C20H25N3O: C, 74.30; H, 7.74;
N, 13.0. Found: C, 74.41; H, 7.73; N, 13.06.
7-Methyl-5,6,8,9,10,11-hexahydropyrido[2,3-c]carbazol-11-one 20
Compound 16 (0.14 g, 0.6 mmol) underwent irradiation under different con-
ditions (see Tables 2, 3). Then, the solvents were evaporated under reduced
pressure. The crude product was chromatographed on alumina gel using
dichloromethane and a gradient of methanol as eluent to give 20 as a white
powder: 22% (best yield), mp 196—198 °C. 1H-NMR (CDCl3) d : 2.17 (2H,
m), 2.45 (2H, t, J6 Hz), 2.74 (2H, t, J8.3 Hz), 2.85 (2H, t, J6.2 Hz),
3.09 (2H, t, J7.8 Hz), 3.63 (3H, s), 7.08 (1H, m), 8.13 (1H, dd, J4.8,
1.6 Hz), 8.79 (1H, dd, J4.2, 1.6 Hz); 13C-NMR (CDCl3) d : 20.2, 22.7, 23.4,
30.5, 32.3, 39.4, 115.9, 117.3, 122.6, 128.4, 132.8, 133.5, 145.2, 145.7,
154.3, 194.1. Anal. Calcd for C16H16N2O: C, 76.19; H, 6.35; N, 11.11.
Found: C, 76.29; H, 6.33; N, 11.15.
7-Ethyl-5,6,8,9,10,11-hexahydropyrido[2,3-c]carbazol-11-one 21
Compound 17 (0.16 g, 0.6 mmol) underwent irradiation under different con-
ditions (see Tables 2, 3). Then, the solvents were evaporated under reduced
pressure. The crude product was chromatographed on alumina gel using
dichloromethane as eluent to give 21 as a yellow oil: 43% (best yield). 1H-
NMR (CDCl3) d : 1.22 (3H, t, J7.2 Hz), 2.08 (2H, m), 2.46 (2H, t,
J6 Hz), 2.73 (4H, m), 3.09 (2H, t, J7.6 Hz), 3.79 (2H, q, J7.2 Hz), 7.07
(1H, m), 8.13 (1H, dd, J4.9, 1.5 Hz), 8.85 (1H, dd, J7.8, 1.5 Hz); 13C-
NMR (CDCl3) d : 16.2, 20.2, 22.5, 23.6, 32.6, 39.1, 39.5, 116.2, 121.0,
122.6, 128.4, 132.1, 133.5, 145.0, 145.3, 154.4, 194.1. Anal. Calcd for
C17H18N2O: C, 76.69; H, 6.77; N, 10.53. Found: C, 76.75; H, 6.78; N, 10.58.
7-(N,N-Diethylaminoethyl)-5,6,8,9,10,11-hexahydropyrido[2,3-c]car-
bazol-11-one 22 Compound 18 (0.4 g, 1.2 mmol) underwent irradiation
under different conditions (see Tables 2, 3). Then, the solvents were evapo-
rated under reduced pressure. The crude product was chromatographed on
alumina gel using ether and a gradient of methanol as eluent to give 22 as a
yellow oil: 38% (best yield). 1H-NMR (CDCl3) d : 0.90 (6H, t, J7.2 Hz),
2.08 (2H, m, H9), 2.47 (6H, m), 2.54 (2H, t, J7.1 Hz), 2.77 (4H, m), 3.09
(2H, t, J7.5 Hz), 3.80 (2H, t, J6.9 Hz), 7.07 (1H, m), 8.13 (1H, d,
J4.1 Hz), 8.84 (1H, dd, J7.9, 1.6 Hz); 13C-NMR (CDCl3) d : 12.4 (2C),
20.5, 22.8, 23.6, 31.3, 39.3, 43.8, 48.1 (2C), 53.5, 116.2, 117.4, 122.6,
128.4, 132.6, 133.4, 145.4, 145.5, 154.5, 194.2. Anal. Calcd for C21H27N3O:
C, 74.78; H, 8.01; N, 12.46. Found: C, 74.90; H, 7.99; N, 12.49.
7-(N,N-Dimethylaminopropyl)-5,6,8,9,10,11-hexahydropyrido[2,3-
c]carbazol-11-one 23 Compound 19 (0.3 g, 0.9 mmol) underwent irradia-
tion under different conditions (see Tables 2, 3). Then, the solvents were
evaporated under reduced pressure. The residue couldn’t be purified by usual
column chromatography techniques, so the proportions of compounds 27
and 23 in the mixture (orange oil) were deduced from proton integrations in
1H-NMR spectrum. Best yield: 32%. 1H-NMR (CDCl3) d : 1.71 (2H, m),
2.06 (2H, m), 2.13 (6H, s), 2.17 (2H, t, J6.7 Hz), 2.45 (2H, t, J6 Hz),
2.74 (4H, m), 3.06 (2H, t, J7.5 Hz), 3.80 (2H, t, J7.5 Hz), 7.06 (1H, m),
8.11 (1H, dd, J4.9, 1.7 Hz), 8.84 (1H, dd, J7.8, 1.7 Hz); 13C-NMR
(CDCl3) d : 20.4, 22.7, 23.7, 28.7, 32.7, 39.4, 42.1, 45.7 (2C), 56.3, 116.1,
117.4, 122.5, 128.4, 132.6, 133.5, 145.4, 145.6, 154.5, 194.2.
7-Methyl-8,9,10,11-tetrahydropyrido[2,3-c]carbazol-11-one 24
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Method 1: Compound 20 (70 mg, 0.3 mmol) was added to a supension of
Pd/carbon 10% (100 mg) in diphenylether (20 ml) and the reaction mixture
was refluxed under nitrogen for 2 h. Still hot, the reaction mixture was fil-
tered in order to eliminate Pd/Carbon, which was washed with a hot mixture
of dichloromethane and methanol (50/50). Dichloromethane and methanol
were evaporated in vacuo and the diphenylether containing the final product
was chromatographed on silica gel using dichloromethane as eluent to elimi-
nate diphenylether and dichloromethane and a gradient of methanol to give
24 as a yellow powder: 30%, mp 214—216 °C.
Method 2: Compound 16 (0.14 g, 0.6 mmol) underwent irradiation under
different conditions (see Tables 2, 3). Then, the solvents were evaporated
under reduced pressure. The crude product was chromatographed on alu-
mina gel using dichloromethane and a gradient of methanol as eluent to give
24 as a yellow powder: 30% (best yield), mp 214—216 °C. 1H-NMR
(CDCl3) d : 2.10 (2H, m), 2.54 (2H, t, J6.0 Hz), 2.67 (2H, t, J6.0 Hz),
3.41 (3H, s), 7.22 (1H, m), 7.39 (1H, d, J9 Hz), 7.80 (1H, d, J9 Hz), 8.78
(1H, dd, J4.3, 1.6 Hz), 10.22 (dd, 1H, J8.5, 1.6 Hz): 13C-NMR (CDCl3)
d : 22.9, 23.1, 30.3, 39.3, 113.7, 115.9, 119.2, 120.9, 123.6, 125.8, 133.9,
137.1, 146.2, 148.4, 151.2, 193.5. Anal. Calcd for C16H14N2O: C, 76.80; H,
5.60; N, 11.20. Found: C, 76.84; H, 5.61; N, 11.24.
7-Ethyl-8,9,10,11-tetrahydropyrido[2,3-c]carbazol-11-one 25 Method
1: Compound 21 (80 mg, 0.3 mmol) was added to a suspension of Pd/carbon
10% (100 mg) in diphenylether (20 ml) and the reaction mixture was re-
fluxed under nitrogen for 2 h. Still hot, the reaction mixture was filtered in
order to eliminate Pd/Carbon, which was washed with a hot mixture of
dichloromethane and methanol (50/50). Dichloromethane and methanol
were evaporated in vacuo and the diphenylether containing the final product
was chromatographed on silica gel using dichloromethane as eluent to elimi-
nate diphenylether and dichloromethane and a gradient of methanol to give
25 as an orange oil: 30%.
Method 2: Compound 17 (0.16 g, 0.6 mmol) underwent irradiation under
different conditions (see Tables 2, 3). Then, the solvents were evaporated
under reduced pressure. The crude product was chromatographed on alu-
mina gel using dichloromethane as eluent to give 25 as an orange oil: 38%
(best yield). 1H-NMR d : 1.37 (3H, t, J7.4 Hz), 2.22 (2H, m), 2.63 (2H, t,
J6.4 Hz), 2.93 (2H, t, J6.2 Hz), 4.17 (2H, q, J7.4 Hz), 7.45 (1H, m),
7.63 (d1H,, J9.1 Hz), 7.93 (1H, d, J9 Hz), 8.79 (1H, dd, J4.4, 1.8 Hz),
10.31 (1H, dd, J8.5, 1.8 Hz); 13C-NMR (CDCl3) d : 15.6, 23.0, 23.4, 39.1,
39.5, 113.9, 116.3, 120.7, 121.0, 124.6, 126.0, 133.2, 137.4, 146.1, 148.2,
150.5, 193.6. Anal. Calcd for C17H16N2O: C, 77.27; H, 6.06; N, 10.61.
Found: C, 77.36; H, 6.09; N, 10.58.
7-(N,N-Diethylaminoethyl)-8,9,10,11-tetrahydropyrido[2,3-c]carbazol-
11-one 26 Compound 18 (0.4 g, 1.2 mmol) underwent irradiation under
different conditions (see Tables 2, 3). Then, the solvents were evaporated
under reduced pressure. The crude product was chromatographed on alu-
mina gel using ether and a gradient of methanol as eluent to give 26 as a yel-
low oil: 23% (best yield). 1H-NMR (CDCl3) d : 0.85 (6H, t, J7.2 Hz), 2.19
(2H, m), 2.46 (4H, q, J7.2 Hz), 2.63 (2H, t, J6.3 Hz), 2.69 (2H, t,
J6.1 Hz), 2.98 (2H, t, J6.3 Hz), 4.14 (2H, t, J6.1 Hz), 7.43 (1H, m),
7.60 (1H, d, J9.1 Hz), 7.89 (1H, d, J9.1 Hz), 8.79 (1H, dd, J4.1,
1.6 Hz), 10.30 (1H, dd, J8.5, 1.6 Hz); 13C-NMR (CDCl3) d : 11.3, 23.4
(2C), 39.4, 43.8, 48.2 (2C), 53.0, 113.9, 116.2, 120.7, 121.0, 124.5, 126.2,
133.5, 137.1, 146.4, 148.5, 151.6, 193.7. Anal. Calcd for C21H25N3O: C,
75.22; H, 7.46; N, 12.54. Found: C, 75.28; H, 7.47; N, 12.49.
7-(N,N-Dimethylaminopropyl)-8,9,10,11-tetrahydropyrido[2,3-c]car-
bazol-11-one 27 Compound 19 (0.3 g, 0.9 mmol) underwent irradiation
under different conditions (see Tables 2, 3). Then, the solvents were evapo-
rated under reduced pressure. The residue couldn’t be purified by usual col-
umn chromatography techniques, so the proportions of compounds 27 and
23 in the mixture (orange oil) were deduced from proton integrations in 1H-
NMR spectrum. Best yield: 45%. 1H-NMR (CDCl3) d : 1.99 (2H, m), 2.30
(10H, m), 2.72 (2H, t, J5.7 Hz), 3.07 (2H, t, J6.2 Hz), 4.31 (2H, t,
J7.0 Hz), 7.52 (1H, m), 7.80 (1H, d, J9.1 Hz), 7.99 (1H, d, J9 Hz), 8.88
(1H, dd, J4.1, 1.6 Hz), 10.38 (1H, dd, J8.5, 1.6 Hz); 13C-NMR (CDCl3)
d : 23.2, 23.5, 28.2, 39.6, 41.9, 45.8 (2C), 56.1, 114.2, 116.3, 120.6, 121.0,
124.5, 126.3, 133.8, 137.1, 146.5, 148.6, 151.2, 194.2.
7H-8,9,10,11-Tetrahydropyrido[2,3-c]carbazol-11-one 38 Compound
37 (50 mg, 0.21 mmol) was added to a suspension of Pd/carbon 10%
(100 mg) in diphenylether (20 ml) and the reaction mixture was refluxed
under nitrogen for 2 h. Still hot, the reaction mixture was filtered in order 
to eliminate Pd/Carbon, which was washed with a hot mixture of
dichloromethane and methanol (50/50). Dichloromethane and methanol
were evaporated in vacuo and the diphenylether containing the final product
was chromatographed on silica gel using dichloromethane as eluent to elimi-
nate diphenylether and dichloromethane and a gradient of methanol to give
38 as a white powder: 30%, mp 223—225 °C. 1H-NMR (CDCl3) d : 2.24
(2H, m), 2.69 (2H, t, J7.1 Hz), 3.03 (2H, t, J6.3 Hz), 7.53 (1H, m), 7.69
(1H, d, J8.9 Hz), 7.87 (1H, d, J9 Hz), 8.79 (1H, dd, J4.2, 1.6 Hz),
10.33 (1H, d, J8.5 Hz); 13C-NMR (CDCl3) d : 23.4, 23.8, 39.2, 116.0,
116.3, 118.9, 119.9, 123.2, 128.2, 132.8, 137.4, 145.2, 147.1, 151.4, 194.1.
Anal. Calcd for C15H12N2O: C, 76.27; H, 5.08; N, 11.86. Found: C, 76.32; H,
5.07; N, 11.91.
Biological Assay Doxorubicin hydrochloride (Pharmacia, St-Quentin en
Yvelines, France), RPMI 1640 medium and fetal calf serum (Polylabo,
Paris, France) were used in this study. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was provided by Sigma (St-Quentin
Fallavier, France). All other reagents were of analytical grade and were ob-
tained from commercial sources.
Cells and Culture: The human leukemic cell line K 562 was obtained
from the American type culture collection (Rockville, MD, U.S.A.). The
human ovarian carcinoma cell line A 2780 was generously given by Dr. P.
Canal (Centre Claudius Régaud, Toulouse). The doxorubicin resistant cell
line A 2780 R was established by the continuous exposure of cells to gradu-
ally increasing concentrations of doxorubicin and was maintained in a
medium supplemented with doxorubicin at 0.1 mg/ml. The MDR phenotype
expression of A 2780 R cell lines was assessed by an immunohistochemistry
method, using the two P-glycoprotein specific murine monoclonal antibody
C219 (Cantocor, Malvern, PA, U.S.A.) and JSB1 (Tebu, Le Perray en Yve-
lines, France). Cultures were grown in RPMI 1460 medium supplemented
with 10% fetal calf serum, antibiotics and glutamine at 37 °C in a humidified
atmosphere containing 5% CO2.
Cytotoxicity Assay: In all the experiments, K 562 and A 2780 cells were
seeded at a final density of 5000 cells/well in 96 well microtiter plates and
were treated with drugs (doxorubicin and compounds 11, 12, 13, 20, 21, 22,
37, 38 and 39). Seven dilutions were used for each drug. After 96 h of incu-
bation, 10 m l of MTT solution in PBS (5 mg/ml, phosphate-buffer saline pH
7.3) were added to each well and the wells were exposed to 37 °C for 4 h.
This colorimetric assay is based on the ability of live and metabolically
unimpaired tumor-cell targets to reduce MTT to a blue formazan product.
Then, 100 m l of a mixture of isopropanol and 1 M hydrochloric acid (96/4,
v/v) were added to each well. After 10 min of vigourous shaking so as to sol-
ubilize formazan crystals, the absorbance was measured on a microculture
plate reader (Dynatech MR 5000, France) at 570 nm. For each assay, at least
three experiments were performed in triplicate. The resistance factor was
calculated from the ratio between the IC50% growth-inhibitory concentra-
tions (IC50 values) recorded from A 2780 R and A 2780 S cells, respectively,
for the following tested drugs: doxorubicin, compounds 11, 12, 13, 20, 21,
22, 37, 38 and 39.
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